Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7227 Neoplasms 4535 Prostatic Neoplasms 3486 Colorectal Neoplasms 2930 Carcinoma, Non-Small-Cell Lung 2823 Lung Neoplasms 2539 Leukemia, Myeloid, Acute 1980 Pancreatic Neoplasms 1870 Multiple Myeloma 1805 Carcinoma, Hepatocellular 1729 Neoplasm Metastasis 1585 Stomach Neoplasms 1498 Lymphoma 1455 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1434 Head and Neck Neoplasms 1430 Brain Neoplasms 1367 Melanoma 1344 Ovarian Neoplasms 1339 Leukemia 1301 Rectal Neoplasms 1266 Recurrence 1249 Colonic Neoplasms 1204 Glioblastoma 1133 Uterine Cervical Neoplasms 1090 Lymphoma, Non-Hodgkin 1064 Leukemia, Lymphocytic, Chronic, B-Cell 989 Esophageal Neoplasms 963 Lymphoma, Follicular 936 Lymphoma, Large B-Cell, Diffuse 931 Squamous Cell Carcinoma of Head and Neck 920

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Interventional × Rare Tumor × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡